Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)

NCT05361720 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT05361720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05361720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
December 6, 2022
Completion date
July 1, 2028
Enrollment
54 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, metastatic clear cell renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8